A comparison of selected dosimetric parameters of two Hodgkin Lymphoma radiotherapy techniques with reference to potential risk of radiation induced heart disease

[1] Halperin EC, Brady LW, Perez CA, et al. Perez & Brady’s Principles and Practice of Radiation Oncology. Wolters Kluwer Health; 2013.Search in Google Scholar

[2] Donaldson SS, Hudson MM, Lamborn KR, et al. VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol. 2002;20(14):3081-3087.10.1200/JCO.2002.12.10112118021Search in Google Scholar

[3] Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854-862.10.1016/j.ijrobp.2013.05.00523790512Search in Google Scholar

[4] Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin’s disease. J Clin Oncol. 2003;21(18):3431-3439.10.1200/JCO.2003.07.13112885835Search in Google Scholar

[5] Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154(1):23-31.10.1111/j.1365-2141.2011.08713.x21539537Search in Google Scholar

[6] Baker JE, Moulder JE, Hopewell JW. Radiation as a risk factor for cardiovascular disease. Antioxid Redox Signalg. 2011;15(7):1945-1956.10.1089/ars.2010.3742315911321091078Search in Google Scholar

[7] Emami B. Tolerance of normal tissue to therapeutic radiation. Rep Rradiother Oncol. 2013;1(1):123-127.Search in Google Scholar

[8] Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3):S77-S85.10.1016/j.ijrobp.2009.04.09320171522Search in Google Scholar

[9] Hahn E, Jiang H, Ng A, et al. Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction. Int J Radiat Oncol Biol Phys. 2017;98(5):1116-1123.10.1016/j.ijrobp.2017.03.02628721895Search in Google Scholar

[10] Jakacki RI, Goldwein JW, Larsen RL, et al. Cardiac dysfunction following spinal irradiation during childhood. J Clin Oncol. 1993;11(6):1033-1038.10.1200/JCO.1993.11.6.10338501489Search in Google Scholar

[11] Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308-1315.10.1200/JCO.2008.20.226720142603Search in Google Scholar

[12] Hoppe R. Hodgkin’s disease: complications of therapy and excess mortality. Ann Oncol. 1997;8(suppl 1):S115-S118.10.1093/annonc/8.suppl_1.S115Search in Google Scholar

[13] Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin’s disease treated at age 50 or younger. J Clin Oncol. 2002;20(8):2101-2108.10.1200/JCO.2002.08.02111956271Search in Google Scholar

[14] Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.10.1093/jnci/djk02917284715Search in Google Scholar

[15] Paumier A, Ghalibafian M, Beaudre A, et al. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2011;80(1):199-205.10.1016/j.ijrobp.2010.09.00721481723Search in Google Scholar

[16] Engert A, Pluetschow A, Eich HT, et al. Combined Modality Treatment of Two or Four Cycles of ABVD Followed by Involved Field Radiotherapy in the Treatment of Patients with Early Stage Hodgkin’s Lymphoma: Update Interim Analysis of the Randomised HD10 Study of the German Hodgkin Study Group (GHSG). Blood. 2005;106(11):2673.10.1182/blood.V106.11.2673.2673Search in Google Scholar

[17] Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin’s disease. Ann Oncol. 2002;13(suppl 1):79-83.10.1093/annonc/13.S1.79Search in Google Scholar

[18] Hoskin P, Díez P, Williams M, et al. Recommendations for the use of radiotherapy in nodal lymphoma. Clin Oncol. 2013;25(1):49-58.10.1016/j.clon.2012.07.01122889569Search in Google Scholar

[19] Herst J, Crump M, Baldassarre F, et al. Management of Early-stage Hodgkin Lymphoma: A Practice Guideline. Clin Oncol. 2017;29(1):e5-e12.10.1016/j.clon.2016.09.00627697411Search in Google Scholar

[20] Campbell BA, Voss N, Pickles T, et al. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin’s lymphoma: a question of field size. J Clin Oncol. 2008;26(32):5170-5174.10.1200/JCO.2007.15.100118838714Search in Google Scholar

[21] Koh E-S, Tran TH, Heydarian M, et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin’s lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007;2:13.10.1186/1748-717X-2-13184751717362522Search in Google Scholar

[22] Koeck J, Abo-Madyan Y, Lohr F, et al. Radiotherapy for early mediastinal Hodgkin lymphoma according to the German Hodgkin Study Group (GHSG): the roles of intensity-modulated radiotherapy and involved-node radiotherapy. Int J Radiat Oncol Biol Phys. 2012;83(1):268-276.10.1016/j.ijrobp.2011.05.05422079733Search in Google Scholar

[23] Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. Wiley; 2011.10.1002/9780471420194.tnmc26.pub2Search in Google Scholar

[24] Khan FM, Gibbons JP. Khan’s The Physics of Radiation Therapy. Wolters Kluwer Health; 2014.Search in Google Scholar

[25] Barrett A, Dobbs J, Roques T. Practical Radiotherapy Planning Fourth Edition. Taylor & Francis; 2009.10.1201/b13373Search in Google Scholar

[26] Carr ZA, Land CE, Kleinerman RA, et al. Coronary heart disease after radiotherapy for peptic ulcer disease. Int J Radiat Oncol Biol Phys. 2005;61(3):842-850.10.1016/j.ijrobp.2004.07.70815708264Search in Google Scholar

[27] van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2015;34(3):235-243.10.1200/JCO.2015.63.444426573075Search in Google Scholar